MSTO211H细胞

MSTO-211H、MSTO-211H、MSTO-211H细胞、MSTO-211H细胞、MSTO-211H人双向性肺癌细胞

Cell line name MSTO-211H

Synonyms MSTO-211 H; MSTO211H; MSTO-211; 211H; MeSoTheliOma-211H

Accession CVCL_1430

Resource Identification Initiative To cite this cell line use: MSTO-211H (RRID:CVCL_1430)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MYC genetic alteration cell panel (ATCC TCP-1035).

Population: Caucasian.

Doubling time: 20 hours (PubMed=2840315); 20 hours (CLS=300450); ~30-40 hours (DSMZ=ACC-390).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).

Gene fusion; HGNC; 6514; LATS1 + HGNC; 9508; PSEN1; Name(s)=LATS1-PSEN1 (PubMed=25902174).

Mutation; HGNC; 6515; LATS2; Simple; p.Met785_Leu798del14 (c.2355_2396del42); Zygosity=Heterozygous (PubMed=21245096; Cosmic-CLP=908152; DepMap=ACH-000335).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*01:01,03:01

HLA-B B*07:02,39:01

HLA-C C*07:02,07:02

Class II

HLA-DR DRB1*01:02,01:02

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0.17

East Asian, North 1.28

East Asian, South 0

South Asian 2.13

European, North 62.92

European, South 33.49

Disease Pleural biphasic mesothelioma (NCIt: C45665)

Pleural mesothelioma (ORDO: Orphanet_50251)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_E0ZC (Ubigene MSTO-211H LDHA KO)

Sex of cell Male

Age at sampling 62Y

Category Cancer cell line

STR profile Source(s): ATCC=CRL-2081; CLS=300450; Cosmic-CLP=908152; DSMZ=ACC-390; Technion Genomics Center

 

Markers:

Amelogenin X,Y

CSF1PO 11,12

D2S1338 20,24

D3S1358 15

D5S818 12

D7S820 8,12

D8S1179 13

D13S317 11,14

D16S539 13

D18S51 16,18 (ATCC=CRL-2081; CLS=300450; DSMZ=ACC-390)

18,19 (Technion Genomics Center)

D19S433 13,14

D21S11 28,31

FGA 21

Penta D 11,12

Penta E 7,13

TH01 8,9.3

TPOX 11

vWA 16,18

 

Run an STR similarity search on this cell line

Publications

PubMed=2840315; DOI=10.1111/j.1432-0436.1988.tb00806.x

Bepler G., Koehler A., Kiefer P., Havemann K., Beisenherz K., Jaques G., Gropp C., Haeder M.

Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.

Differentiation 37:158-171(1988)

 

PubMed=15920167; DOI=10.1016/S0002-9440(10)62492-3; PMCID=PMC1363736

Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G., Sugarbaker D.J., Bueno R.

Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Am. J. Pathol. 166:1827-1840(2005)

 

PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x; PMCID=PMC11158456

Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.

Cancer Sci. 97:387-394(2006)

 

PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x; PMCID=PMC11158069

Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K., Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M., Sekido Y.

Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.

Cancer Sci. 98:438-446(2007)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164

Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.

LATS2 is a tumor suppressor gene of malignant mesothelioma.

Cancer Res. 71:873-883(2011)

 

PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098

Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Nat. Genet. 43:668-672(2011)